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AbstractThere has been evidence supporting the reduction of depression and anxiety by religious psychotherapy in cancer patients, however, there have been scarce randomized controlled trials. Therefore, there is a need for replication in a well-designed 
study to investigate the efficacy of these interventions among depressed women with breast cancer. A randomized controlled trial is designed to be conducted on 160 women with breast cancer. Participants will be screened for anxiety 
and depression diagnosed by clinical interview based on the DSM-IV criteria and the Hospital Anxiety Depression Scale. 
Golriz and Baraheni’s Religious Attitude Questionnaire will be used to assess the religious attitude. Individuals meeting the prerequisites will be randomly allocated to four groups, each containing 40 participants, including three intervention 
groups (RCBT, CBT, and citalopram) and one control group (usual breast cancer treatment). An instrument by the 
EORTCQLQ-C30 and BR-23 will be used to measure the quality of life. Blood tests will be taken to assess biomarkers with 
the (ELISA) method. The results will determine whether RCBT is more effective than other treatments. If so, the outcomes of the study will have implications not only for the management of similar problems in cancer patients but also for the management of other chronic diseases.
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1.  Background
Breast cancer is one of the most common malignancies 
among women worldwide1,2. It has been observed that 
diagnosis, surgery, chemotherapy, and radiotherapy 
may contribute to psychological symptoms3,4, cognitive 
malfunction5-7, and changes in daily life8,9. Recently, 
researchers have emphasized the relationship between 
psycho-neuro-immunological factors and depression10,11. 
Several studies have shown significant increases in the 
production of pro-inflammatory cytokines (IL-6, TNF-α)12, 
and (IFN-γ) among depressed patients12,13, although 
anti-inflammatory cytokines such as IL-10modulate 
depressive-like behavior14,15. However, the results of other 
studies have shown no association between depression 
and cytokines16,17. There are several effective treatments 
for anxiety , depression and normalization of cytokines. 
From the psychiatric point of view, pharmacological 
therapies have been considered as first-line treatments for 
mental disorders18. As a second-generation antidepressant 
drug, citalopram has recently been extensively used in the 
treatment of depression symptoms19. Decreases in the 
anxiety symptoms along with those of depression and a 
lack of interaction with tamoxifen, which prevents breast 
cancer relapse, are the other advantages of this drug20. 
However, drug interventions and their side effects may 
cause problems for most patients even when prescribing 
serotonin selective reuptake inhibitor (SSRI) as safety 
drugs21. Instead, psycho-spiritual therapy as a non-
pharmacological intervention has proven to be a useful 
treatment modality22,23. There has been evidence to support 
decreases in psychological problems24,25, reductions in 
adverse biological changes26-28 and improvements in 
the quality of life using religious intervention in cancer 
patients29-31, particularly when the interventions are based 
on a cognitive-behavioral structure29,32,33. Nonetheless, 
few randomized controlled trials in religious therapy 
have been conducted29,34 and there are conflicting 
results35,36. Furthermore, some studies have reported 
serious limitations in methodology9,29,37,38. Accordingly, 
there is a need replication in a more definitive and well-
designed study to evaluate the effects of RCBT, CBT, and 
citalopram, on anxiety, depression, and biomarkers levels 
in women with breast cancer. This article includes the 
protocol of the study, while the findings will be presented 
when the study is accomplished.
2.  Objectives and Hypotheses
The aim of this study is twofold. First, the study compares 
the effects of RCBT, CBT, and citalopram on anxiety and 
depression, in women with breast cancer. The secondary 
aims will be to compare the effects of RCBT, CBT, and 
citalopram on the quality of life, and biomarkers levels 
of IL6, IL10, and TNF-α, IFN-γ, DHEA, and cortisol, in 
women with breast cancer.
It is hypothesized that RCBT will be more effective 
than CBT and citalopram on anxiety, depression, quality 
of life and biomarkers levels of IL6, IL10, TNF-α, IFN-γ, 
DHEA  and cortisol in women with breast cancer. 
3.  Outcome 
The primary outcome will be reductions in the anxiety 
and depression scores immediately, and at 6, 9, and 12 
months after the intervention. The secondary outcomes 
are increases in the quality of life scores immediately 
and at 6, 9, and 12 months after the interventions, and 
normalizing biomarkers levels immediately and 12 
months after the intervention. 
4.   Methods and Design 
This study was approved by the Behavioral Sciences 
Research Center in Mazandaran University of Medical 
Science (2013-12-04), and we have received an ethical 
consensus from the Ethics Committee in the Research 
Deputy of Mazandaran University of Medical Sciences 
(92193) that is fully compliant with the Helsinki 
Declaration of 2008. This randomized controlled trial with 
parallel groups is supposed to evaluate the effect of RCBT 
compared to CBT, citalopram, and usual breast cancer 
treatment on the reduction of anxiety and depression in 
women with breast cancer in Tuba Clinic in Sari. This 
center was located in Northern Iran. The participants 
will be randomly allocated to one of three intervention 
groups (RCBT, CBT, or citalopram) and one control 
group (usual breast cancer treatment). Participants will 
have been referred to this center for follow-up treatment 
from throughout the province.
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4.1 Inclusion Criteria
1) Women with breast cancer who are being treated in Tuba 
Clinic. 2) Age of less than 65 years. 3)  Being at a clinical 
level of 1, 2 or 3 for breast cancer. 4) Having undergone 
surgery, chemotherapy, or radiotherapy. 5) Ability to 
understand and communicate in Farsi. 6) Education level 
of junior middle school or higher. 7) Meeting the DSM-
IV criteria for anxiety and depression39. 8) Obtaining a 
score of ≥8 for depression and anxiety based in HADS 
(Iranian version)40. 9) Providing written consent for study 
participation and 10) Expressing religious41.
4.2 Exclusion Criteria
1) Participants with known psychiatric history such as 
schizophrenia, bipolar disorder, and serious suicidal 
thoughts based on the clinical interview (DSM-IV) 
performed by a psychiatrist. 2) Participants with a 
history of physical illnesses or any kind of malignancy 
preventing them from attending the treatment sessions. 
3) Participants who have taken part in RCBT or CBT 
or other psychotherapy courses, and 4) Patients taking 
citalopram for the previous 2 weeks.
5.  Procedure
The researcher will first assess archived records related to 
women with breast cancer referred to Tuba Clinic. After 
applying the inclusion and exclusion criteria, patients 
who meet the required conditions will be selected. Then, 
the researcher will contact the patients and briefly explain 
the study. If patient agree to participate in the study 
(oral consent), they will be invited to participate at Tuba 
Clinic at the appointed time. All participants will be 
asked if they are religious people (yes or no); for those 
who answered yes, their religious attitude intensity will 
be determined by using Golriz and Baraheni’s religious 
attitude questionnaire (Iranian version)42. If their score 
is above 25, they will be enrolled in this trial. At the 
baseline assessment, inclusion and exclusion criteria 
will be checked again and participants will be informed 
about the details of the research project by the researcher. 
After obtaining the written consent, the researcher will 
give them the HADS questionnaire to assess anxiety and 
depression symptoms. Participants with HADS scores 
of 8 and more will be referred to a psychiatrist for a 
clinical interview based on the DSM-IV. Participants 
with mental disorders such as schizophrenia, bipolar 
disorder, and serious thoughts of suicide will be excluded 
and referred to treatment. Thereafter, to assess quality 
of life, the researcher will use a questionnaire by the 
European Organization for Research and Treatment of 
Cancer Quality of Life (EORTCQLQ-C30) and a breast 
cancer specific questionnaire (BR-23)43. Blood tests will 
be taken to assess biomarker levels of IL6, IL10, TNF-α, 
IFN-γ, DHEA, and cortisol with ELISA method. Eligible 
participants will be randomly allocated to the intervention 
or control groups. The therapists will have completed 
training courses related to RCBT and CBT interventions. 
Then, the intervention will be performed by therapists. 
Assessments will be conducted at baseline, immediately 
after intervention, and at 6, 9, and 12 months after the 
intervention. Participants will be called once every 2 
weeks throughout the study, so that their problems and 
probable questions can be addressed. Table 1 shows the 
different assessment times of the questionnaires. Figure 1 
contains the expected participant flow chart.
Table 1.    Measurement of outcome variables, at baseline (pre intervention), immediately after intervention, 6, 9 and 12 
months after intervention
Variable Measurement tool Time of assessment 
Baseline    after intervention 6 9 12 month after intervention 
Depression  and anxiety Hospital anxiety  and depression * * * * * 
Clinical interview DSM -IV  *
Religious attitude Golriz and Baraheni’s religious 
attitude
*
Quality of life  EORTCQLQ-C30 & BR-23 * * * * *
Blood test Biomarkers 
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5.1 Randomization
Eligible participants are selected based on random 
numbers from the table and then randomly allocated 
into four groups of 40. Participants are randomized 
using block randomization to ensure equal group sizes. 
Randomization will be stratified by age (≤48, ≥48) and 
level of education (≤ high middle school, and ≥ high 
middle school). The participants will be informed about 
the treatments and control groups after randomization.
5.2 Sampling
Participants will be recruited from Tuba Clinic and, 
to account for any attrition that may occur, multiple 
imputations will be used. Furthermore, by increasing the 
number of the participants up to 25%, to the study will 
lessen the attrition rate. According to previous studies44 
with α = 5% and a power analysis of 80%, the number 
of participants needed has been determined to be 160 
patients, with 40 in each group.
5.3 Instrumentation
Structured clinical interview (DSM-IV): A psychiatrist 
will conduct a structured clinical interview based on 
the DSM-IV. If the patient has any kind of mental 
disorders (bipolar, schizophrenia, serious suicidal 
thoughts) diagnosed, or the patient has a history of taking 
psychiatric drugs, we will exclude him/her from the study 
and refer him/her to a psychiatrist to be treated. Hospital 
Anxiety Depression Scale (HADS): This scale contains 14 
questions including two parts measuring depression and 
anxiety. The scale has four options and each answer is 
scored from 0 to 3.The validity and reliability of this scale 
in Iran has been confirmed. This instrument has been 
found reliable with α Cranach’s index of 0.78 for anxiety 
and 0.86 for depression40.The European Organization for 
Research and Treatment of Cancer Quality of Life Group 
(EORTC QLG) will be used to measure quality of life 
in the patients43. The another questionnaire used is the 
breast cancer specific questionnaire (BR-23)45. These two 
questionnaires were translated and validated in Persian46. 
Gloria and Baraheni’s Religious Attitude Questionnaire: 
This religious Iranian questionnaire contains 25 questions 
in a five-point Likert-scale from zero to four (the 
maximum total score is 100)47.
Figure 1.    Flowchart of study design. 
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5.4 Blood Test
To measure the biomarkers of IL6, IL10, DHEA, cortisol, 
TNF- α and IFN- γ, blood tests will be obtained by a 
laboratory expert (research assistant) in the laboratory 
of Tuba Clinic in Sari. It will be conducted before, 
immediately after the intervention. From each participant, 
5–7 cc peripheral blood in the form of a clot will be 
obtained; the serums will be immediately extracted and 
divided into small amounts to be transmitted to the lab 
of the cellular and molecular biology research center. 
Then, it will be stored in cold chain compliance in −80°C 
up to the experiment date. All stages of transmission and 
processing will be identical for all samples in all four 
groups. Cytokines of TFN- α, IFN- γ, IL-6, and IL-10 will 
be tested using the sandwich ELISA method.
5.5 Interventions
After randomization, the RCBT and CBT groups will 
receive 12 one-hour weekly sessions of an intervention 
along with their usual breast cancer treatment. The drug 
intervention group will receive citalopram 20–40 mg every 
evening based on a physician’s order accompanied by usual 
breast cancer treatment for 3 months. The control group 
will receive only usual breast cancer treatment. During 
the interventions and after that, the research assistant will 
call the participants in all of the groups, every 2 weeks 
to monitor and ensure their well-being. If the symptoms 
worsen, they will be excluded from the study and will be 
referred to psychiatrists for further treatment.
5.6 Cognitive Behavioral Therapy
Cognitive behavioral therapy is an interactional approach 
that helps participants to develop treatment strategies 
via the dynamic modification of cognition and behavior. 
According to the protocol and treatment techniques 
developed by Beck48, the topics of each session will already 
be determined. To meet the specific needs of the patients 
with breast cancer, the techniques developed by the Becks 
will be modified.
5.7  Religious Cognitive Behavioral 
Intervention
A researcher-made RCBT manual will be devised with 
the structure and content adapted from Judith Beck’s 
cognitive-behavior model. RCBT teaches patients 
to use their own religious teachings, doctrines, and 
behaviors to help change the maladaptive beliefs, 
values, and behaviors20.  This model will be modified to 
be applicable for the interventions related to religious. 
Religious concepts such as faith and trust, prayer, sacred, 
relationship with God, by searching the religious books, 
literature and electronic sources under the supervision 
of experts will be collected. In this way, Iranian socio-
cultural backgrounds will be considered. 
5.8 Pharmacologic Intervention
Citalopram 20–40 mg will be administered to this group 
every evening based on a psychiatrist’s order for 3 months 
in addition to the usual breast cancer treatment. During 
this period, they will be visited every 2 weeks and will be 
questioned about the concomitant use of medications 
and symptoms, side effects, and illnesses. This way, if 
participants display adverse effects, they will be excluded 
from the study and refer to a psychiatrist for follow-up 
treatment. Citalopram will be provided from Sobhan 
Pharmaceutical Company in Iran in the form of oral 
tablets in 20 and 40 mg dosages; it has been officially 
licensed by Iran Health Ministry.
6.   Usual Breast Cancer 
Treatment
The control group will solely receive the usual breast 
cancer treatment, which refers to physical care, 
medication, nutrition, activities, routine psychological 
care, and periodic visits for follow-up. An instructional 
pamphlet containing this information will be given to 
the patients. Similar to other three groups, the research 
assistant will monitor this group once every 2 weeks via 
telephone. If the symptoms worsen, they will be excluded 
from the study and will be referred to psychiatrists for 
further treatment.
7.  Data Analysis
The data will be analyzed with SPSS for Windows, version 
20. Descriptive statistics (mean frequency and percentage) 
and analytical statistics (t-test, chi-square, ANOVA, log 
rank test, Cox regression, Kaplan–Meier, and survival 
analysis) will be employed to analyze the collected data. 
ANCOVA and regression will also be employed for 
stratifying data by age and levels of education.
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8.  Discussion
This study will be conducted to investigate the effects of 
RCBT compared to CBT and citalopram therapy on the 
depression and anxiety of women suffering from breast 
cancer. The findings of this study will indicate whether 
RCBT can work more efficiently than other interventions 
in the treatment of depression, anxiety, and physiological 
changes caused by these comorbidities. If so, the 
outcomes of the study will have implications not only 
for religious psychological management in breast cancer 
but also for the management of similar problems in other 
chronic diseases. This article includes the protocol of the 
study, and findings will be presented when the study is 
accomplished.
9.  Safety Aspects and Medical 
Complications
Attention should be paid to safety parameters including 
the diagnosis of mental disorders and serious problems 
throughout the treatment and 1-year follow-up.
Recording the adverse effects that may occur during 
the intervention and the following 12 months, as they 
may lead to death, life-threatening issues, a need for 
hospitalization, and everything leading to resistance to 
treatment and inability in the patient.
Recording every type of adverse effects diagnosed 
during the study according to clinical interviews by the 
psychiatrist and coding in the report forms.
Every diagnosed adverse effect should be reported to 
the Ethics Committee.
10.  Ethics
The participants will be informed about the purpose 
of the study and will be assured about the safety of the 
interventions. They will be also made aware of the 
confidentiality of their personal information. Permission 
for doing the project came from Ethics Committee of 
Research Deputy of Mazandaran University of Medical 
Sciences and from Tuba Specialist Clinic. Every question 
posed by the participants will be answered by the 
researcher. Participation is voluntary and participants 
will be informed that they can withdraw their consent to 
participate at any time. Written consent will be obtained 
from all the participants. Because the participants get 
tired quickly, all interviews will be brief. The RCBT and 
CBT therapists have passed the relevant courses, have the 
experience in this regard, and can identify thoughts of 
suicide and refer them to the clinic. The therapists will 
work under the supervision of experts to support the 
participants.
11.  The Strengths of the Study
A control group who will be treated with usual therapies 
will be included in the study. Effects of the intervention 
will be assessed in a long-term follow-up. Due to a 
design using comparative strategy to directly compare 
three intervention groups, this clinical trial will have 
external validity and the findings of this study will 
directly be applied in practice. One of the most important 
strengths of external validity is the outcome assessment. 
Furthermore, this clinical trial enjoys internal validity 
because the therapists follow the treatment protocol, as 
well as calculating the inter-rater reliability of the primary 
outcome and employing reliable and valid instruments. 
Group therapy using a cognitive behavioral intervention 
is another advantage of this intervention. The group 
members are also satisfied since they help each other and 
interact during the group meetings in RCBT and CBT. 
This results in higher self-confidence, a sense of social 
competence, and a sense of belonging. 
12.  Limitations of the Study
Blinding is not possible for participants and therapists, 
though the statistician is blind. This will minimize the 
effect of information bias. Another limitation of the 
study is the amount of time devoted to individuals in the 
RCBT and CBT interventions. The unwillingness of the 
patients to present their problems in group discussions 
and their embarrassment is another clinical concern of 
the researcher.
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